Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters

Database
Language
Affiliation country
Publication year range
1.
Expert Opin Investig Drugs ; 15(1): 13-21, 2006 Jan.
Article in English | MEDLINE | ID: mdl-16370930

ABSTRACT

Cholesterol can promote inflammation by its ability to stimulate the production of reactive oxygen species that result in the formation of pro-inflammatory oxidised phospholipids. High-density lipoproteins (HDLs) are part of the innate immune response and can be either pro- or anti-inflammatory independently of plasma HDL-cholesterol levels. During systemic inflammation as occurs with atherosclerosis, Apolipoprotein A-I can be altered, reducing its ability to promote reverse cholesterol transport and HDL can become pro-inflammatory. Amphipathic peptides with either a class A amphipathic helix (D-4F) or a class G* amphipathic helix (D-[113-122]apoJ), or even those that are too small to form a helix (KRES and FREL) have some similar characteristics. Their interaction with lipids leads to a reduction in lipoprotein-lipid hydroperoxides that releases HDL-associated antioxidant enzymes, such as paraoxonase, therefore providing antiatherosclerosis and anti-inflammatory activity. In addition, the peptide D-4F stimulates the formation and cycling of pre-beta HDL. These amphipathic peptides appear to have therapeutic potential as oral agents.


Subject(s)
Anti-Inflammatory Agents/therapeutic use , Atherosclerosis/drug therapy , Peptides/therapeutic use , Administration, Oral , Animals , Anti-Inflammatory Agents/administration & dosage , Anti-Inflammatory Agents/chemistry , Apolipoprotein A-I/chemistry , Atherosclerosis/immunology , Atherosclerosis/metabolism , Cholesterol/immunology , Cholesterol/metabolism , Clusterin/chemistry , Disease Models, Animal , Drug Evaluation, Preclinical , Endothelial Cells/metabolism , Humans , Immunity, Innate , Inflammation/immunology , Inflammation/metabolism , Lipoproteins, HDL/immunology , Lipoproteins, HDL/metabolism , Molecular Mimicry , Peptides/administration & dosage , Peptides/chemistry , Protein Structure, Secondary
2.
Circulation ; 109(25): 3215-20, 2004 Jun 29.
Article in English | MEDLINE | ID: mdl-15197147

ABSTRACT

BACKGROUND: These studies were designed to determine the mechanism of action of an oral apolipoprotein (apo) A-I mimetic peptide, D-4F, which previously was shown to dramatically reduce atherosclerosis in mice. METHODS AND RESULTS: Twenty minutes after 500 microg of D-4F was given orally to apoE-null mice, small cholesterol-containing particles (CCPs) of 7 to 8 nm with pre-beta mobility and enriched in apoA-I and paraoxonase activity were found in plasma. Before D-4F, both mature HDL and the fast protein liquid chromatography fractions containing the CCPs were proinflammatory. Twenty minutes after oral D-4F, HDL and CCPs became antiinflammatory, and there was an increase in HDL-mediated cholesterol efflux from macrophages in vitro. Oral D-4F also promoted reverse cholesterol transport from intraperitoneally injected cholesterol-loaded macrophages in vivo. In addition, oral D-4F significantly reduced lipoprotein lipid hydroperoxides (LOOH), except for pre-beta HDL fractions, in which LOOH increased. CONCLUSIONS: The mechanism of action of oral D-4F in apoE-null mice involves rapid formation of CCPs, with pre-beta mobility enriched in apoA-I and paraoxonase activity. As a result, lipoprotein LOOH are reduced, HDL becomes antiinflammatory, and HDL-mediated cholesterol efflux and reverse cholesterol transport from macrophages are stimulated.


Subject(s)
Apolipoprotein A-I/pharmacology , Apolipoproteins E/deficiency , Arteriosclerosis/genetics , Cholesterol/metabolism , Hyperlipoproteinemia Type II/genetics , Lipoproteins, HDL/biosynthesis , Macrophages, Peritoneal/drug effects , Administration, Oral , Amino Acid Sequence , Animals , Apolipoprotein A-I/therapeutic use , Apolipoproteins E/genetics , Arteriosclerosis/blood , Aryldialkylphosphatase/blood , Biological Transport/drug effects , Cells, Cultured , Chemotaxis/drug effects , Coculture Techniques , Drug Evaluation, Preclinical , Female , High-Density Lipoproteins, Pre-beta , Humans , Hyperlipoproteinemia Type II/blood , Inflammation , Lipid Peroxidation/drug effects , Lipoproteins, HDL/blood , Macrophages, Peritoneal/metabolism , Mice , Mice, Inbred C57BL , Mice, Knockout , Molecular Sequence Data , Monocytes/cytology , Monocytes/drug effects , Monocytes/metabolism
3.
Circulation ; 108(14): 1735-9, 2003 Oct 07.
Article in English | MEDLINE | ID: mdl-14504179

ABSTRACT

BACKGROUND: Lecithin has been widely sold as a dietary supplement. 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) is a phospholipid that does not exist in nature and has been used in vitro to study lipid binding. We tested DMPC in vivo in apolipoprotein (apo) E-null mice. METHODS AND RESULTS: DMPC or soy or egg lecithin at 1.0 mg/mL was added to the drinking water of 4-week-old apoE-null female mice. Eight weeks later, HDL cholesterol levels and apoA-I levels were markedly increased in the mice that received DMPC. HDL function was also dramatically improved in the mice receiving DMPC, and there was a significant reduction in aortic lesions (P=0.021) in the DMPC mice but not in those receiving lecithin. Adding 1.0 mg/mL of DMPC to the drinking water of 10-month-old apoE-null female mice for 5 weeks caused regression of aortic sinus lesions (P=0.003). Adding 1.0 mg/mL DMPC to the drinking water of 6-month-old apoE-null male mice for 8 weeks significantly reduced aortic sinus lesion area (P=0.0031) and en face whole aorta lesion area (P=0.001), whereas adding the same concentrations of soy or egg lecithin did not significantly alter lesion area. Jejunal apoA-I synthesis and plasma apoA-I levels were increased 2- to 3-fold in mice receiving DMPC but not soy or egg lecithin. CONCLUSIONS: DMPC (but not lecithin) raises HDL cholesterol and apoA-I, improves HDL function, and prevents lesions or causes their regression in apoE-null mice.


Subject(s)
Arteriosclerosis/drug therapy , Cholesterol, HDL/blood , Dimyristoylphosphatidylcholine/therapeutic use , Lipoproteins, HDL/physiology , Administration, Oral , Animals , Apolipoprotein A-I/biosynthesis , Apolipoprotein A-I/blood , Apolipoproteins E/genetics , Arteriosclerosis/blood , Arteriosclerosis/pathology , Chemotaxis , Coculture Techniques , Dimyristoylphosphatidylcholine/administration & dosage , Dimyristoylphosphatidylcholine/pharmacology , Female , Male , Mice , Mice, Knockout , Monocytes/physiology
4.
Vascul Pharmacol ; 38(4): 211-8, 2002 Apr.
Article in English | MEDLINE | ID: mdl-12449017

ABSTRACT

Oxidized-L-alpha-1-Palmitoyl-2-Arachidonoyl-sn-glycero-3-Phosphorylcholine (Ox-PAPC), a component of mildly oxidized/minimally modified low-density lipoprotein (MM-LDL), accounts for many of the biological activities of MM-LDL. Having hypothesized that Ox-PAPC initiates gene expression changes in endothelial cells that result in enhanced endothelial/monocyte interactions and the subsequent development of atherosclerotic lesions, we used the suppression subtractive hybridization (SSH) procedure to compare mRNA isolated from PAPC-treated human aortic endothelial cells (HAEC) with mRNA isolated from Ox-PAPC-treated cells. Genes induced by Ox-PAPC but not by PAPC in HAEC included genes involved in signal transduction, extracellular matrix, growth factors, chemokines and several genes with unknown functions. The observed pattern of gene induction suggests that Ox-PAPC may play multiple roles in angiogenesis, atherosclerosis, and inflammation and wound healing.


Subject(s)
Aorta, Thoracic/cytology , Endothelium, Vascular/cytology , Gene Expression Regulation/drug effects , Phosphatidylcholines/pharmacology , Phospholipids/pharmacology , Aorta, Thoracic/drug effects , Blotting, Northern , Chemokines/pharmacology , Cloning, Molecular , DNA, Complementary/biosynthesis , DNA, Complementary/genetics , Endothelium, Vascular/drug effects , Extracellular Matrix/drug effects , Extracellular Matrix/metabolism , Growth Substances/pharmacology , Humans , In Vitro Techniques , Inflammation/genetics , Inflammation/pathology , Lipoproteins, LDL/metabolism , Neovascularization, Pathologic/genetics , Neovascularization, Pathologic/pathology , Nucleic Acid Hybridization , Oxidation-Reduction , RNA, Messenger/biosynthesis , RNA, Messenger/genetics , Signal Transduction/drug effects , Transcriptional Activation
SELECTION OF CITATIONS
SEARCH DETAIL